Subkutan implantierbarer Kardioverter-Defibrillator: eine Alternative?

Literatur

• 1 Almendral J, Arribas F, Wolpert C, Ricci R, Adragao P, Cobo E, Navarro X, Quesada A. DATAS Steering Committee; DATAS Writing Committee; DATAS Investigators . Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial.  Europace. 2008;  10 528-535
• 2 Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients.  PACE. 2005;  28 926
• 3 Connolly S J, Gent M, Roberts R S, Dorian P, Roy D, Sheldon R S, Mitchell L B, Green M S, Klein G J, O’Brien B. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone.  Circulation. 2000;  101 1297-1302
• 4 Maytin M. Multicenter experience with extraction of the Sprint Fidelis implantable cardioverter-defibrillator lead.  J AM Coll Cardiol. 2010;  56 646
• 5 Moss A J, Zareba W, Hall W J, Klein H, Wilber D J, Cannom D S, Daubert J P, Higgins S L, Brown M W, Andrews M L. Multicenter Automatic Defibrillator Implantation Trial II Investigators . Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.  N Engl J Med. 2002;  346 877-883
• 6 Trappe H J. Subkutan implantierbarer Kardioverter-Defibrillator: eine Alternative? Viele Fragen bleiben offen.  Dtsch Med Wochenschr. 2010;  135 1586